Coenzyme Q10 (injectable)
/ Coenzyme Q10 (ubiquinone); injectable research-grade preparation; mitochondrial electron transport cofactorALIAS · CoQ10 (injectable) · Ubiquinone · Coenzyme Q10
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 2. Small-to-moderate randomised trials of oral CoQ10 in heart failure (Q-SYMBIO), cardiac surgery preconditioning, and statin-associated myalgia. Injectable research-grade preparations sit outside FDA-approved channels in the US; oral ubiquinone and ubiquinol formulations are sold as dietary supplements and have generated most of the human evidence base.
Coenzyme Q10 (ubiquinone, 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone) is a lipid-soluble redox-active quinone that shuttles electrons from complexes I and II to complex III in the inner mitochondrial membrane electron transport chain. The reduced ubiquinol form additionally functions as an endogenous lipid-phase antioxidant, regenerating alpha-tocopherol from the tocopheroxyl radical and protecting membrane phospholipids from peroxidation.
Endogenous biosynthesis declines with age and is suppressed by HMG-CoA reductase inhibition, providing the mechanistic rationale for the statin-associated myalgia literature. Plasma CoQ10 rises with oral supplementation but tissue partitioning to mitochondria-rich organs (myocardium, skeletal muscle, brain) is limited and formulation-dependent; the ubiquinol form and lipid-emulsified preparations show higher relative bioavailability than crystalline ubiquinone in pharmacokinetic comparisons.
Tier 2. The Q-SYMBIO trial (Mortensen and colleagues, JACC Heart Failure 2014) randomised 420 participants with chronic heart failure (NYHA III-IV) to CoQ10 100 mg three times daily or placebo for two years and reported reductions in the composite endpoint of major adverse cardiovascular events. Cardiac-surgery preconditioning trials (Rosenfeldt and colleagues 2007) reported myocardial recovery improvements. Multiple smaller trials in statin-associated myalgia have produced mixed results.
Generally well-tolerated across decades of supplement use. Reported adverse events at oral doses up to 600 mg/day include mild gastrointestinal upset, headache, and rash. CoQ10 may reduce warfarin anticoagulation through structural similarity to vitamin K2; monitoring INR is recommended in concurrent use. Injectable research-grade preparations carry the additional concerns inherent to any non-approved parenteral product (sterility, endotoxin, identity, purity).
Regulatory status
- FDA status:
- Not FDA-approved
The injectable framing is largely a research-vendor presentation; the published clinical literature is predominantly oral. Tissue penetration of CoQ10 to mitochondria-rich organs is a longstanding pharmacokinetic concern and has driven development of mitochondrially-targeted analogs (MitoQ, idebenone) that are pharmacologically distinct from native ubiquinone. Q-SYMBIO has not been independently replicated at the same scale; subsequent meta-analyses (including a 2017 Cochrane review) have called for larger confirmatory trials.